Recently, a team from Fujian Medical University found that MEG3 mediated meningioma cell cycle arrest through miR-29c/A-kinase anchoring protein 12 (AKAP12) axis and inhibited tumor cell migration, invasion, and proliferation; thus, providing a new biomarker for the treatment of meningioma (Ding et al., 2020). Here, AKAP12 is linked to neoplasm.